Vital Transformation understands the implications of new medical procedures, technologies and policies. We measure their impact on current clinical practices in close collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders. Vital Transformation has presented or participated in conferences sponsored by The Royal College of Physicians, European Health Forum Gastein, The European Commission, London Genetics, The European Science Foundation, The European Microelectronics Summit, and others. Our Vital Transformation branded round-tables, webinars, and conferences are often oversubscribed, and are regularly presented in partnership with global thought-leaders and organisations.
OUR RESEARCH
Innovation Requires a New Regulatory Framework to Improve Research and Development of New Medical Therapies
20th June, 2013
By Duane Schulthess
For targeted medicines, the current processes of regulatory evaluation, decision frameworks and delivery systems are limiting the implementation of new, better therapies. A healthcare ecosystem designed to enable innovation must also support R&D that is cost effective for all stakeholders and make-good on the promise that innovative medicines can effectively deliver the right prevention and treatment to the right patient at the right time.
Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?
September, 2012
Abstract
This study is a cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome – a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of €4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (−59%), Angioplasty (−59%), Bypass (−17%), Medication (−14%) and Rehabilitation (−13%).
Unlocking the value of personalised healthcare in Europe—breast cancer stratification
June, 2012
Abstract
Through stratification, this simulation shows that there is great potential to improve the efficiency of treating breast cancer. By segmenting the female population at the age of 50 based on family history and genetic testing, our model shows a reduction in costs of breast cancer treatments by 37% with no loss of efficacy accomplished primarily through a 60% drop in incidence of metastatic stages of the disease
PODCASTS
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
Our clients include many of the world’s leading health care organisations.
